ArticleBMC nephrology2025
The impact of asymptomatic kidney stones on disease progression in autosomal dominant polycystic kidney disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between nephrolithiasis and kidney disease progression in patients with autosomal dominant polycystic kidney disease: a prospective cohort study.Clinical kidney journal · 2026Article
- Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.Renal failure · 2025Review
- A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal Dominant Polycystic Kidney Disease (ADPKD) is a common hereditary disorder leading to end-stage kidney disease due to the progressive formation of renal cysts. Nephrolithiasis is a frequent complication of ADPKD, with a prevalence significantly higher than in the general population. However, its role in disease progression remains underexplored. This study investigates the impact of asymptomatic nephrolithiasis on kidney function decline in ADPKD patients.
methodsA retrospective cohort of 195 ADPKD patients was followed at our nephrology clinic. Of these, 85 patients had nephrolithiasis (N+), and 110 did not (N-). Data on demographic characteristics, biochemical parameters, and kidney function were collected. ΔeGFR (change in eGFR over time) served as the primary outcome. Statistical analyses, including correlation and multiple linear regression, were performed to assess the predictors of ΔeGFR.
resultsThe N + group exhibited a significantly greater decline in kidney function compared to the N- group (ΔeGFR: 16.53 vs. 12.82 mL/min/1.73 m², p = 0.008). Lower calcium levels were observed in the N + group (p = 0.007), potentially reflecting metabolic abnormalities linked to nephrolithiasis. Nephrolithiasis was independently associated with kidney function decline (B = 3.159, p = 0.038). Follow-up duration was strongly associated with ΔeGFR (p < 0.001). Age showed a trend toward significance but did not reach statistical significance.
conclusionAsymptomatic nephrolithiasis is associated with accelerated kidney function decline in ADPKD patients. These findings highlight the importance of monitoring kidney stones, even in the absence of symptoms, to mitigate their impact on renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.